Xilio Therapeutics (XLO) Other Working Capital Changes (2020 - 2026)

Xilio Therapeutics has disclosed Other Working Capital Changes across 7 years of filings, most recently posting $1.2 million for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $1.2 million, up 225.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.0 million (up 511.14% YoY), and the FY2025 annual result was $27.9 million, down 14.96% from the prior year.
• Other Working Capital Changes came in at $1.2 million for Q1 2026 at Xilio Therapeutics, down from $30.5 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $39.1 million in Q1 2024 to a low of -$40.7 million in Q3 2025.
• The 5-year median for Other Working Capital Changes is -$239000.0 (2023), against an average of $3.6 million.
• Across the five-year window, Other Working Capital Changes soared 18468.08% in 2024 and plunged 1698.9% in 2025, its largest moves.
• Xilio Therapeutics' Other Working Capital Changes stood at $939000.0 in 2022, then plunged by 125.45% to -$239000.0 in 2023, then slumped by 621.34% to -$1.7 million in 2024, then soared by 1866.65% to $30.5 million in 2025, then slumped by 96.04% to $1.2 million in 2026.
• The last three Other Working Capital Changes figures came in at $1.2 million (Q1 2026), $30.5 million (Q4 2025), and -$40.7 million (Q3 2025), per Business Quant data.